These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 9951491)

  • 1. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.
    Shulman DG; Lothringer LL; Rubin JM; Briggs RB; Howes J; Novack GD; Hart K
    Ophthalmology; 1999 Feb; 106(2):362-9. PubMed ID: 9951491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis.
    Dell SJ; Lowry GM; Northcutt JA; Howes J; Novack GD; Hart K
    J Allergy Clin Immunol; 1998 Aug; 102(2):251-5. PubMed ID: 9723669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.
    Pflugfelder SC; Maskin SL; Anderson B; Chodosh J; Holland EJ; De Paiva CS; Bartels SP; Micuda T; Proskin HM; Vogel R
    Am J Ophthalmol; 2004 Sep; 138(3):444-57. PubMed ID: 15364229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group.
    Dell SJ; Shulman DG; Lowry GM; Howes J
    Am J Ophthalmol; 1997 Jun; 123(6):791-7. PubMed ID: 9535623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
    Abelson M; Howes J; George M
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis.
    Ilyas H; Slonim CB; Braswell GR; Favetta JR; Schulman M
    Eye Contact Lens; 2004 Jan; 30(1):10-3. PubMed ID: 14722462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis.
    Asbell P; Howes J
    CLAO J; 1997 Jan; 23(1):31-6. PubMed ID: 9001768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.
    Gong L; Sun X; Qu J; Wang L; Zhang M; Zhang H; Wang L; Gu Y; Elion-Mboussa A; Roy L; Zhu B
    Clin Ther; 2012 Jun; 34(6):1259-1272.e1. PubMed ID: 22627057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of loteprednol etabonate nasal spray suspension on seasonal allergic rhinitis assessed by allergen challenge in an environmental exposure unit.
    Krug N; Hohlfeld JM; Geldmacher H; Larbig M; Heermann R; Lavallee N; Nguyen DT; Petzold U; Hermann R
    Allergy; 2005 Mar; 60(3):354-9. PubMed ID: 15679722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I.
    Friedlaender MH; Howes J
    Am J Ophthalmol; 1997 Apr; 123(4):455-64. PubMed ID: 9124242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nedocromil sodium 2% ophthalmic solution for the treatment of ragweed pollen seasonal allergic conjunctivitis.
    Blumenthal MN; Schwartz RH; Kaiser H
    Ocul Immunol Inflamm; 2000 Sep; 8(3):159-67. PubMed ID: 11120577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
    Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
    Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
    Berdy GJ; Stoppel JO; Epstein AB
    Clin Ther; 2002 Jun; 24(6):918-29. PubMed ID: 12117082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change in intraocular pressure during long-term use of loteprednol etabonate.
    Novack GD; Howes J; Crockett RS; Sherwood MB
    J Glaucoma; 1998 Aug; 7(4):266-9. PubMed ID: 9713785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis.
    Bartlett JD; Howes JF; Ghormley NR; Amos JF; Laibovitz R; Horwitz B
    Curr Eye Res; 1993 Apr; 12(4):313-21. PubMed ID: 8319490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2.
    Ophthalmology; 1998 Sep; 105(9):1780-6. PubMed ID: 9754192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.
    Macejko TT; Bergmann MT; Williams JI; Gow JA; Gomes PJ; McNamara TR; Abelson MB;
    Am J Ophthalmol; 2010 Jul; 150(1):122-127.e5. PubMed ID: 20488431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery.
    Rajpal RK; Roel L; Siou-Mermet R; Erb T
    J Cataract Refract Surg; 2013 Feb; 39(2):158-67. PubMed ID: 23218817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.
    Sheppard JD; Donnenfeld ED; Holland EJ; Slonim CB; Solomon R; Solomon KD; McDonald MB; Perry HD; Lane SS; Pflugfelder SC; Samudre SS
    Eye Contact Lens; 2014 Sep; 40(5):289-96. PubMed ID: 25083776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.